AnaptysBio Inc. Common Stock (ANAB)
Stock · NASDAQ · Health Care
$46.6as of 10/16/2026
Price chart
Active signals
ANAB Signal Track Record
How signals performed across all stocks →What ANAB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +3.4% | 62% | September 18, 2026 |
| Bollinger Band Breakout | 30 | -4.3% | 40% | August 17, 2026 |
| Bollinger Band Breakdown | 15 | -3.5% | 47% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +7.0% | 88% | October 1, 2026 |
| Any 20-session window (baseline) | +2.8% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANAB
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 104
- Website
- www.anaptysbio.com/
Fundamentals
- 1-day range
- $45.99$46.78
- Market cap
- $1.62B
- P/E (trailing)
- 7.14
- P/E (forward)
- 9.08
- EPS (trailing)
- $3.34
- Dividend yield
- —
- Beta
- 0.81
- Avg. volume
- 564.3K
How AnaptysBio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
AnaptysBio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANABAnaptysBio Inc. Common Stock$46.61▼ 4.31%Market cap $1.62BP/E 7.14$20.18$72.36
- MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock$6.79▼ 3.96%Market cap $1.61BP/E —$2.55$9.42
- TYRATyra Biosciences Inc. Common Stock$18.52▼ 2.73%Market cap $1.61BP/E —$12.96$40.65
- AAPGAscentage Pharma Group International American Depository Shares$15.37▲ 4.63%Market cap $1.60BP/E —$27.12$75.1
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- ZYMEZymeworks Inc. Common Stock$25.03▼ 2.80%Market cap $1.69BP/E —$16$31.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANAB AnaptysBio Inc. Common Stock | $1.62B | 7.14 | $46.61 | ▼ 4.31% | $20.18$72.36 |
| MRVI Maravai LifeSciences Holdings Inc. Class A Common Stock | $1.61B | — | $6.79 | ▼ 3.96% | $2.55$9.42 |
| TYRA Tyra Biosciences Inc. Common Stock | $1.61B | — | $18.52 | ▼ 2.73% | $12.96$40.65 |
| AAPG Ascentage Pharma Group International American Depository Shares | $1.60B | — | $15.37 | ▲ 4.63% | $27.12$75.1 |
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| ZYME Zymeworks Inc. Common Stock | $1.69B | — | $25.03 | ▼ 2.80% | $16$31.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty StoryYahoo · 10/9/2026
- AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% RiseYahoo · 10/8/2026
- JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60Benzinga · 9/30/2026
- AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash PerformanceYahoo · 9/26/2026
- AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?Yahoo · 9/26/2026
- HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price TargetBenzinga · 9/24/2026
- Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81Benzinga · 9/23/2026
- AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesYahoo · 9/21/2026
Insider Activity
Insider Actions →- Hollings Renton · October 1, 2026 · Option Exercise5.0K @ $18.03
- Hollings Renton · October 1, 2026 · Sale5.0K @ $49.87
- John A. Orwin · September 15, 2026 · Option Exercise1.3K
- John A. Orwin · June 15, 2026 · Option Exercise6.0K
- Hollings Renton · June 15, 2026 · Option Exercise6.0K
- John P. Schmid · June 15, 2026 · Option Exercise6.0K
- Murphy Christopher M. · May 11, 2026 · Grant25.8K
- Hughes Owen · May 11, 2026 · Grant11.3K
- GRAY SUSANNAH · April 27, 2026 · Grant11.3K
- Daniel Faga · April 20, 2026 · Disposition11.0K
- Daniel Faga · April 20, 2026 · Grant133.4K
- Daniel Faga · April 20, 2026 · Disposition133.4K
- Daniel Faga · April 20, 2026 · Grant305.5K
- Daniel Faga · April 20, 2026 · Disposition305.5K
- Daniel Faga · April 20, 2026 · Grant379.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 27.57M
- Total value held
- $1.50B
- Institutional holders
- 199
- Unknown7.88M
- Unknown1.68M
- Unknown1.33M
- Unknown993.9K
- Unknown992.4K
- Unknown940.0K
- Unknown853.2K
- Unknown821.9K
- Unknown638.2K
- Unknown625.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AnaptysBio News Mixes Valuation Views With Litigation Risks
Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.
AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.